Back to top
more

Merck & Co. (MRK)

(Delayed Data from NYSE)

$113.69 USD

113.69
11,918,995

+0.60 (0.53%)

Updated Sep 27, 2024 04:00 PM ET

After-Market: $113.60 -0.09 (-0.08%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (45 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Merck (MRK) to Report Q1 Earnings: What's in the Cards?

Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda when the company reports Q1 earnings.

Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know

Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?

Sector ETF report for XPH

Analysts Estimate Merck (MRK) to Report a Decline in Earnings: What to Look Out for

Merck (MRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Merck (MRK) Dips More Than Broader Markets: What You Should Know

In the latest trading session, Merck (MRK) closed at $114.13, marking a -0.61% move from the previous day.

Biotech Stock Roundup: MDGL, PCVX Up on Study Data, MRNA Provides Updates

Pipelines updates from Madrigal (MDGL) and Vaxcyte, (PCVX) are the key highlights of the biotech sector.

Company News for Apr 18, 2023

Companies in The News Are: MTB,RXDX,NFLX,ANET,MRK

Prometheus Biosciences, Inc. (RXDX) Stock Jumps 69.7%: Will It Continue to Soar?

Prometheus Biosciences, Inc. (RXDX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Moderna (MRNA), Merck's Cancer Jab Delays Melanoma Recurrence

Detailed data from a mid-stage study shows that Moderna (MRNA)/Merck's personalized cancer vaccine candidate reduces the risk of recurrence/death.

Prometheus (RXDX) Stock Surges 70% on Buyout Offer From Merck

Prometheus (RXDX) is set to be acquired by Merck for $11 billion, adding Prometheus' lead product candidate, PRA023, to Merck's portfolio. Prometheus' stock is up 70%.

Mark Vickery headshot

Top Analyst Reports for Eli Lilly, Thermo Fisher Scientific & Lockheed Martin

Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Thermo Fisher Scientific Inc. (TMO) and Lockheed Martin Corporation (LMT).

Merck's (MRK) Keytruda sBLA Accepted by FDA for Gastric Cancer

Merck's (MRK) application seeking approval for Keytruda in combination with fluoropyrimidine- and platinum-containing chemotherapy for the early treatment of locally advanced, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma was accepted by the FDA.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Rejects LLY's Mirikizumab, NVO Ups 2023 Sales & Profit View

FDA issues CRL to Eli Lilly's (LLY) BLA seeking approval of mirikizumab for ulcerative colitis (UC). Novo Nordisk (NVO) ups sales and profit outlook for 2023.

Mark Vickery headshot

Markets Rally on Cooler Economic Data; More Results on Deck

Weaker economic prints are beginning to reveal an alternative narrative: perhaps the Fed has done enough already.

Merck (MRK) Outpaces Stock Market Gains: What You Should Know

Merck (MRK) closed the most recent trading day at $115.58, moving +1.61% from the previous trading session.

Fusion (FUSN) to Begin Clinical Study on Targeted Alpha Therapy

Fusion (FUSN) surges after investigational new drug application clearance by the FDA for its targeted alpha therapy FPI-2068, co-developed with AstraZeneca.

Moderna (MRNA), Merck's Cancer Jab Gets EMA's PRIME Tag

The EMA grants PRIME designation to Moderna's (MRNA) personalized cancer vaccine candidate combined with Merck's Keytruda for treating certain types of melanoma.

Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It

Zacks.com users have recently been watching Merck (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

The Zacks Analyst Blog Highlights J&J, AstraZeneca, Merck, Seagen and Pfizer

J&J, AstraZeneca, Merck, Seagen and Pfizer are part of the Zacks Top Analyst Blog.

Merck (MRK) Keytruda Studies in Difficult-to-Treat Cancers Fail

Merck (MRK) and Eisai announce the discontinuation of the phase III LEAP-003 study seeking approval of the Keytruda and Lenvima combo. Another phase III LEAP-017 study fails to meet goals.

Zacks Investment Ideas feature highlights: Nvidia, United Healthcare, Merck, Pfizer and Intuitive Surgical

Nvidia, United Healthcare, Merck, Pfizer and Intuitive Surgical are part of the Zacks Investment Ideas article.

Is Invesco Dynamic Pharmaceuticals ETF (PJP) a Strong ETF Right Now?

Smart Beta ETF report for PJP

Will Bristol Myers (BMY) Gain From New Drugs' Label Expansion?

Label expansion of Bristol Myers' (BMY) new drugs should help it somewhat combat the decline in Revlimid sales due to generic competition.

Kinjel Shah headshot

Pharma Stock Roundup: J&J's $8.9B Offer for Talc Litigation Settlement & Other Updates

J&J (JNJ) offers a $8.9 billion settlement to resolve its talc lawsuits. FDA approves Merck's (MRK) Keytruda plus Seagen's Padcev for a bladder cancer indication.

Andrew Rocco headshot

3 Reasons to Buy Healthcare Stocks in the Current Market Environment

Healthcare stocks are currently providing investors with an attractive way to counterbalance a portfolio overexposed to tech. In general, healthcare stocks have lower betas, are more defensive, and have cleaner balance sheets.